Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Anna A. Iliukhina"'
Autor:
Daria S. Fomina, Marina S. Lebedkina, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Sergey S. Andreev, Anton A. Chernov, Inna V. Dolzhikova, Tatyana S. Kruglova, Gerelma V. Andrenova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Alexander V. Karaulov, Maryana A. Lysenko, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Several virus-neutralizing monoclonal antibodies (mAbs) have become new tools in the treatment of the coronavirus disease (COVID-19), but their effectiveness against the rapidly mutating virus is questionable. The present study investigated the effec
Externí odkaz:
https://doaj.org/article/670820e7fe5d4672ba2d2ca795a32834
Autor:
Amir I. Tukhvatulin, Ilya V. Gordeychuk, Inna V. Dolzhikova, Alina S. Dzharullaeva, Marina E. Krasina, Ekaterina O. Bayurova, Daria M. Grousova, Anna V. Kovyrshina, Alla S. Kondrashova, Daria V. Avdoshina, Stanislav A. Gulyaev, Tatiana V. Gulyaeva, Andrey V. Moroz, Viktoria V. Illarionova, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Andrei G. Botikov, Alina S. Erokhova, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Olga V. Zubkova, Elisaveta A. Tokarskaya, Daria M. Savina, Yulia R. Vereveyko, Anastasiya S. Ungur, Boris S. Naroditsky, Aydar A. Ishmukhametov, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Emerging Microbes and Infections, Vol 11, Iss 1, Pp 2229-2247 (2022)
Although unprecedented efforts aiming to stop the COVID-19 pandemic have been made over the past two years, SARSCoV-2 virus still continues to cause intolerable health and economical losses. Vaccines are considered the most effective way to prevent i
Externí odkaz:
https://doaj.org/article/8a8e17e744c744cc8415e7fd4b98dfbe
Autor:
Amir I. Tukhvatulin, Inna V. Dolzhikova, Alina S. Dzharullaeva, Daria M. Grousova, Anna V. Kovyrshina, Olga V. Zubkova, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Alina S. Erokhova, Olga Popova, Tatiana A. Ozharovskaia, Denis I. Zrelkin, Fatima M. Izhaeva, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Elisaveta A. Tokarskaya, Natalia A. Nikitenko, Nadezhda L. Lubenets, Elizaveta A. Khadorich, Vladimir A. Gushchin, Svetlana N. Borzakova, Anna V. Vlasova, Ismail M. Osmanov, Valerii V. Gorev, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
To protect young individuals against SARS-CoV-2 infection, we conducted an open-label, prospective, non-randomised dose-escalation Phase 1/2 clinical trial to evaluate the immunogenicity and safety of the prime-boost “Sputnik V” vaccine administe
Externí odkaz:
https://doaj.org/article/eccefe49c05d44c496a720e9225bf865
Autor:
Ilias B. Esmagambetov, Ekaterina I. Ryabova, Artem A. Derkaev, Dmitry V. Shcheblyakov, Inna V. Dolzhikova, Irina A. Favorskaya, Daria M. Grousova, Mikhail A. Dovgiy, Vladimir V. Prokofiev, Andrey I. Gosudarev, Daria V. Byrikhina, Ilia D. Zorkov, Anna A. Iliukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionNumerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In cont
Externí odkaz:
https://doaj.org/article/435734489115452892c1fe539af6307b
Autor:
Andrei A. Pochtovyi, Daria D. Kustova, Andrei E. Siniavin, Inna V. Dolzhikova, Elena V. Shidlovskaya, Olga G. Shpakova, Lyudmila A. Vasilchenko, Arina A. Glavatskaya, Nadezhda A. Kuznetsova, Anna A. Iliukhina, Artem Y. Shelkov, Olesia M. Grinkevich, Andrei G. Komarov, Denis Y. Logunov, Vladimir A. Gushchin, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 11, Iss 10, p 1533 (2023)
The spread of COVID-19 continues, expressed by periodic wave-like increases in morbidity and mortality. The reason for the periodic increases in morbidity is the emergence and spread of novel genetic variants of SARS-CoV-2. A decrease in the efficacy
Externí odkaz:
https://doaj.org/article/57f79b7d9ac54e95bfbe7cde0f6c9b00
Autor:
Vladimir A. Gushchin, Darya A. Ogarkova, Inna V. Dolzhikova, Olga V. Zubkova, Igor V. Grigoriev, Andrei A. Pochtovyi, Anna A. Iliukhina, Tatiana A. Ozharovskaia, Nadezhda A. Kuznetsova, Daria D. Kustova, Artem Y. Shelkov, Denis I. Zrelkin, Alina S. Odintsova, Daria M. Grousova, Vladislav Y. Kan, Sona A. Davtyan, Andrei E. Siniavin, Elizaveta D. Belyaeva, Andrei G. Botikov, Arina A. Bessonova, Lyudmila A. Vasilchenko, Daria V. Vasina, Denis A. Kleymenov, Egor A. Slutskiy, Artem P. Tkachuk, Olga A. Burgasova, Svetlana Y. Loginova, Evgeny V. Rozhdestvensky, Dmitry V. Shcheblyakov, Alexander N. Tsibin, Andrey G. Komarov, Vladimir I. Zlobin, Sergei V. Borisevich, Boris S. Naroditsky, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
WHO has declared the outbreak of monkeypox as a public health emergency of international concern. In less than three months, monkeypox was detected in more than 30 000 people and spread to more than 80 countries around the world. It is believed that
Externí odkaz:
https://doaj.org/article/84ad75d454a44bc8b7f615c5d10c8ed5
Autor:
Irina A. Favorskaya, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Inna V. Dolzhikova, Irina A. Alekseeva, Anastasia I. Korobkova, Daria V. Voronina, Ekaterina I. Ryabova, Artem A. Derkaev, Anna V. Kovyrshina, Anna A. Iliukhina, Andrey G. Botikov, Olga L. Voronina, Daria A. Egorova, Olga V. Zubkova, Natalia N. Ryzhova, Ekaterina I. Aksenova, Marina S. Kunda, Denis Y. Logunov, Boris S. Naroditsky, Alexandr L. Gintsburg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibod
Externí odkaz:
https://doaj.org/article/f07abc82d4394ceda24adf1504e604ad
Autor:
Vladimir A. Gushchin, Inna V. Dolzhikova, Alexey M. Shchetinin, Alina S. Odintsova, Andrei E. Siniavin, Maria A. Nikiforova, Andrei A. Pochtovyi, Elena V. Shidlovskaya, Nadezhda A. Kuznetsova, Olga A. Burgasova, Liudmila V. Kolobukhina, Anna A. Iliukhina, Anna V. Kovyrshina, Andrey G. Botikov, Aleksandra V. Kuzina, Daria M. Grousova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Olga V. Zubkova, Oksana V. Karpova, Olga L. Voronina, Natalia N. Ryzhova, Ekaterina I. Aksenova, Marina S. Kunda, Dmitry A. Lioznov, Daria M. Danilenko, Andrey B. Komissarov, Artem P. Tkachuck, Denis Y. Logunov, Alexander L. Gintsburg
Publikováno v:
Vaccines, Vol 9, Iss 7, p 779 (2021)
Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7,
Externí odkaz:
https://doaj.org/article/0b31c283f51e46aabe29d31600c5e309
Autor:
Ekaterina I Ryabova, Dmitry V. Shcheblyakov, Denis Y. Logunov, Andrey G Botikov, Alexandr L. Gintsburg, Irina A Alekseeva, Ekaterina I. Aksenova, Irina A Favorskaya, Olga L. Voronina, Artem A Derkaev, Natalia N. Ryzhova, Boris S. Naroditsky, M.S. Kunda, Anna V. Kovyrshina, Ilias B Esmagambetov, Daria V Voronina, Daria A. Egorova, Inna V. Dolzhikova, Anna A. Iliukhina, Anastasia I Korobkova, Olga V. Zubkova
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::953137976c48f1113918d4e21bcf2bb8
https://doi.org/10.1101/2021.11.24.469842
https://doi.org/10.1101/2021.11.24.469842
Autor:
Elena V. Shidlovskaya, Anna A. Iliukhina, Alina S. Odintsova, Dmitry V. Shcheblyakov, Olga L. Voronina, Vladimir A. Gushchin, Daria M. Grousova, Inna V. Dolzhikova, M.S. Kunda, Shchetinin Am, Alexander L. Gintsburg, Ekaterina I. Aksenova, A. I. Tukhvatulin, Andrei A. Pochtovyi, Olga A. Burgasova, Liudmila V. Kolobukhina, Natalia N. Ryzhova, Daria Danilenko, Artem P. Tkachuck, Botikov Ag, Olga V. Zubkova, Oksana V. Karpova, Andrey Komissarov, Nadezhda A. Kuznetsova, Aleksandra V. Kuzina, Denis Y. Logunov, Anna V. Kovyrshina, Dmitry Lioznov, Andrei E. Siniavin, Maria A. Nikiforova
Publikováno v:
Vaccines; Volume 9; Issue 7; Pages: 779
Vaccines, Vol 9, Iss 779, p 779 (2021)
Vaccines
Vaccines, Vol 9, Iss 779, p 779 (2021)
Vaccines
Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aec9bf5f6fa698614be65908abfd72be